Form D · Biotechnology
Abexxa Biologics, Inc.
Arlington, TX · CIK 0001684213
Offering snapshot reported Sep 19, 2016 · SEC filing
- Reported sold
- $1.25M Offering amount: $1.75M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 7, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 19, 2016 | Initial | $1,249,999 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-270910
Source: Form D, filed Sep 19, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Martin Heidecker | Director |
| Jon Weidanz | Director, Executive |
| Debra Weidanz | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Nanofab Building, 500 S. Cooper St. #203
Arlington, TX, 76019
Arlington, TX, 76019